Loading...
Loading...
Browse all stories on DeepNewz
VisitWhich AI tool will be most widely adopted for cellular metabolism modeling by pharmaceutical companies by December 31, 2024?
EPFL's RENAISSANCE • 25%
University of Michigan's AI tool • 25%
AlphaFold-Multimer • 25%
Other • 25%
Industry reports and official announcements from pharmaceutical companies
AI Tools Like RENAISSANCE Revolutionize Antibody Discovery and Metabolism Modeling
Sep 2, 2024, 07:48 AM
Recent advancements in artificial intelligence (AI) are significantly enhancing the field of drug discovery and cellular metabolism modeling. Researchers at the University of Michigan, led by Peter Tessier, PhD, are utilizing AI to optimize antibody discovery by balancing multiple attributes such as affinity and manufacturability. This approach aims to expedite the development of antibody therapeutics for clinical use. Additionally, a new AI tool is being developed to predict protein functions within various cellular environments, potentially improving the efficiency of drug discovery. At EPFL, researchers have created an AI tool to generate precise models of cellular metabolism, simplifying the understanding of cell functions. The generative machine learning framework, RENAISSANCE, has been introduced to efficiently parameterize large-scale kinetic models of metabolism, offering accurate characterization of intracellular metabolic states. A study compares six state-of-the-art methods, including AlphaFold-Multimer, for predicting antibody–antigen complex structures from sequences, highlighting systematic biases.
View original story
Insilico Medicine • 25%
Amgen • 25%
Terray Therapeutics • 25%
Other • 25%
Google DeepMind • 25%
Microsoft • 25%
IBM • 25%
Other • 25%
Insilico Medicine • 25%
Amgen • 25%
Nested Therapeutics • 25%
Other • 25%
Machine Learning • 25%
Deep Learning • 25%
Natural Language Processing • 25%
Other AI technologies • 25%
Claude 3.5 Sonnet • 33%
GPT-4o • 33%
Google's AI Model • 33%
OpenAI's O1 model • 25%
GPT-4 • 25%
Gemini • 25%
Anthropic's Claude • 25%
Machine Learning • 25%
Deep Learning • 25%
Natural Language Processing • 25%
Other • 25%
AskResearchGPT • 25%
JPMorgan's AI tool • 25%
Goldman Sachs AI tool • 25%
Other • 25%
UNI • 25%
Virchow • 25%
Prov-GigaPath • 25%
nuclei • 25%
Significant cost reduction • 25%
Faster drug development • 25%
Increased collaboration with AI companies • 25%
All of the above • 25%
Meta • 25%
OpenAI • 25%
Anthropic • 25%
Other • 25%
Meta's Llama 3.1-70B • 25%
OpenAI's GPT-4 quantized • 25%
Google's Bard quantized • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Other • 25%
University of Michigan's AI tool • 25%
AlphaFold-Multimer • 25%
EPFL's RENAISSANCE • 25%